Impromen

Bromperidol, the active ingredient in Impromen, is a butyrophenone presented as an oral formulation for oral use. It is employed in the management of schizophrenia and acute psychotic episodes in adult patients.

GNH USA supplies Impromen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Impromen, a typical antipsychotic of the butyrophenone class, is used to treat disorders that involve dopaminergic overactivity.

- Schizophrenia: helps reduce positive symptoms such as hallucinations, delusions, and thought disorder, facilitating stabilization of chronic illness. - Acute psychotic episodes: provides rapid control of severe agitation, psychosis, and behavioral disturbances, allowing safe management in emergency or inpatient settings.

Bromperidol may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Extrapyramidal symptoms: muscle rigidity, tremor, or akathisia. - Sedation or drowsiness. - Dry mouth and constipation. - Dizziness or orthostatic hypotension.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: fever, rigidity, autonomic instability. - Tardive dyskinesia: persistent involuntary movements. - Agranulocytosis: severe reduction in white blood cells.

Before initiating bromperidol therapy, clinicians should assess patient‑specific risk factors and monitor for potential complications.

- Extrapyramidal monitoring: observe for early signs of movement disorders and adjust therapy as needed. - Cardiovascular assessment: evaluate baseline ECG and blood pressure, especially in patients with cardiac disease. - Hepatic function: check liver enzymes periodically in patients with hepatic impairment. - Elderly caution: start at the lowest effective dose and monitor for sedation or falls. - Discontinuation: avoid abrupt cessation to reduce risk of rebound psychosis. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Bromperidol can interact with other medications, altering efficacy or safety.

Major Interactions (Avoid): - CNS depressants (e.g., benzodiazepines, opioids): may enhance sedation and respiratory depression. - Antihypertensives: additive hypotensive effect. - QT‑prolonging agents (e.g., certain antiarrhythmics, macrolide antibiotics): increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs: may mask extrapyramidal symptoms. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): can raise bromperidol plasma levels, requiring dose adjustment.